| Name | Title | Contact Details |
|---|
ADARx is a genetic medicine company focusing on the editing of Messenger RNA Targeting transcripts and oligonucleotide-based therapeutics.
Vince and Associates Clinical Research is a Overland Park, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Care Solace is a social purpose organization founded with the mission to implement systemic solutions for sustainable, equitable access to mental health care. Providing a human and technology approach, Care Solace navigates the mental health care system and finds the right help for everyone in every community regardless of coverage, including private insurance, Medicaid, and sliding scale options for those without insurance. We match individuals to more than 350,0000 verified providers, perform a Warm Handoff®, and follow-up on care. Care Solace expands on existing social programs and employer EAPs and bridges the gaps for needs that exceed the scope of those services. Founded in 2017, Care Solace has proudly completed over 6.5 million support interactions across 600 organizations nationwide.
Omnicare, Inc., a Fortune 500 company based in Cincinnati, Ohio, provides comprehensive pharmaceutical services to patients and providers across the United States. As the market-leader in professional pharmacy, related consulting and data management services for skilled nursing, assisted living and other chronic care institutions, Omnicare leverages its unparalleled clinical insight into the geriatric market along with some of the industry's most innovative technological capabilities to the benefit of its long-term care customers. Omnicare also provides key commercialization services for the bio-pharmaceutical industry through its Specialty Care Group. Directly and through our subsidiaries, Omnicare works to help ensure the health of seniors and other patient populations in a cost-effective manner.
Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers. Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.